Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

Next Previous
Trial Profile

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Navtemadlin (Primary) ; Danazol; Hydroxycarbamide; Lenalidomide; Peginterferon alfa-2a; Prednisone
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms BOREAS
  • Sponsors Kartos Therapeutics

Most Recent Events

  • 15 Jun 2023 Results (at data cutoff 06Jan 2023, n=113 ) evaluating correlations between biomarkers of disease burden and survival outcomes (progression-free survival[PFS] and OS) , presented at the 28th Congress of the European Haematology Association
  • 14 Dec 2021 Primary endpoint has been met. ((Part A Only) Spleen Volume Reduction (SVR))
  • 14 Dec 2021 Results assessing correlations between changes in biomarkers of disease burden presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top